Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The clinical impact of ponatinib on the risk of bleeding in patients with chronic myeloid leukemia.

Literature DB >> 24091930

The clinical impact of ponatinib on the risk of bleeding in patients with chronic myeloid leukemia.

Aziz Nazha¹, Carlos G Romo, Hagop Kantarjian, Jorge Cortes.
1. jcortes@mdanderson.org.

Abstract

Entities: Chemical Disease Species

Keywords: bleeding; chronic myeloid leukemia; ponatinib

Mesh：

Substances：

Year: 2013 PMID： 24091930 PMCID： PMC3789475 DOI： 10.3324/haematol.2013.091678

Source DB: PubMed Journal: Haematologica ISSN： 0390-6078 Impact factor: 9.941

× No keyword cloud information.

5 in total

1. Platelet dysfunction associated with ponatinib, a new pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitor therapy.

Authors: Pratap Neelakantan; David Marin; Mike Laffan; John Goldman; Jane Apperley; Dragana Milojkovic
Journal: Haematologica Date: 2012-04-24 Impact factor: 9.941

2. Fyn and Lyn phosphorylate the Fc receptor gamma chain downstream of glycoprotein VI in murine platelets, and Lyn regulates a novel feedback pathway.

Authors: L S Quek; J M Pasquet; I Hers; R Cornall; G Knight; M Barnes; M L Hibbs; A R Dunn; C A Lowell; S P Watson
Journal: Blood Date: 2000-12-15 Impact factor: 22.113

Review 3. Clinical utility of the PFA-100.

Authors: Emmanuel J Favaloro
Journal: Semin Thromb Hemost Date: 2009-02-12 Impact factor: 4.180

4. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.

Authors: Thomas O'Hare; William C Shakespeare; Xiaotian Zhu; Christopher A Eide; Victor M Rivera; Frank Wang; Lauren T Adrian; Tianjun Zhou; Wei-Sheng Huang; Qihong Xu; Chester A Metcalf; Jeffrey W Tyner; Marc M Loriaux; Amie S Corbin; Scott Wardwell; Yaoyu Ning; Jeffrey A Keats; Yihan Wang; Raji Sundaramoorthi; Mathew Thomas; Dong Zhou; Joseph Snodgrass; Lois Commodore; Tomi K Sawyer; David C Dalgarno; Michael W N Deininger; Brian J Druker; Tim Clackson
Journal: Cancer Cell Date: 2009-11-06 Impact factor: 31.743

5. Physical and functional association of the Src family kinases Fyn and Lyn with the collagen receptor glycoprotein VI-Fc receptor gamma chain complex on human platelets.

Authors: Y Ezumi; K Shindoh; M Tsuji; H Takayama
Journal: J Exp Med Date: 1998-07-20 Impact factor: 14.307

5 in total

Review 1. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia.

Authors: J L Steegmann; M Baccarani; M Breccia; L F Casado; V García-Gutiérrez; A Hochhaus; D-W Kim; T D Kim; H J Khoury; P Le Coutre; J Mayer; D Milojkovic; K Porkka; D Rea; G Rosti; S Saussele; R Hehlmann; R E Clark
Journal: Leukemia Date: 2016-04-28 Impact factor: 11.528

5. Varying effects of tyrosine kinase inhibitors on platelet function-A need for individualized CML treatment to minimize the risk for hemostatic and thrombotic complications?

Authors: Suryyani Deb; Niklas Boknäs; Clara Sjöström; Anjana Tharmakulanathan; Kourosh Lotfi; Sofia Ramström
Journal: Cancer Med Date: 2019-11-12 Impact factor: 4.452

5 in total

The clinical impact of ponatinib on the risk of bleeding in patients with chronic myeloid leukemia.

1. Platelet dysfunction associated with ponatinib, a new pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitor therapy.

2. Fyn and Lyn phosphorylate the Fc receptor gamma chain downstream of glycoprotein VI in murine platelets, and Lyn regulates a novel feedback pathway.

Review 3. Clinical utility of the PFA-100.

4. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.

5. Physical and functional association of the Src family kinases Fyn and Lyn with the collagen receptor glycoprotein VI-Fc receptor gamma chain complex on human platelets.

Review 1. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia.

2. Tyrosine Kinase Inhibitor Pazopanib Inhibits Platelet Procoagulant Activity in Renal Cell Carcinoma Patients.

3. Ponatinib Activates an Inflammatory Response in Endothelial Cells via ERK5 SUMOylation.

Review 4. Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia.

5. Varying effects of tyrosine kinase inhibitors on platelet function-A need for individualized CML treatment to minimize the risk for hemostatic and thrombotic complications?